开拓药业(09939.HK)普克鲁胺治疗新冠重症患者死亡风险降低92%
开拓药业(09939.HK)表示,旗下普克鲁胺治疗COVID-19重症患者的临床试验结果显示,普克鲁胺於第14天达到主要终点,表明世界卫生组织COVID-19等级量表下由5.663的基线下降4.01至1.653。同时,结果显示,普克鲁胺可降低92%患者死亡风险(3.7%对比47.6%),并缩短住院时间中位数9天(住院时间中位数5天对比14天)。
临床试验设置男性及女性两个队列,每个队列分为普克鲁胺组及对照组两个组别,最初招募588名符合所有资格标准的患者。在普克鲁胺组中,患者将每日口服一次(QD) 300毫克普克鲁胺,持续14天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.